ATE323701T1 - Triazolopyridine als entzündungshemmende mittel - Google Patents

Triazolopyridine als entzündungshemmende mittel

Info

Publication number
ATE323701T1
ATE323701T1 AT02710260T AT02710260T ATE323701T1 AT E323701 T1 ATE323701 T1 AT E323701T1 AT 02710260 T AT02710260 T AT 02710260T AT 02710260 T AT02710260 T AT 02710260T AT E323701 T1 ATE323701 T1 AT E323701T1
Authority
AT
Austria
Prior art keywords
triazolopyridines
inflammatory agents
inflammatory
agents
Prior art date
Application number
AT02710260T
Other languages
English (en)
Inventor
Mark A Dombroski
Allen J Duplantier
Ellen R Laird
Michael A Letavic
Kim F Mcclure
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE323701T1 publication Critical patent/ATE323701T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02710260T 2001-03-09 2002-02-08 Triazolopyridine als entzündungshemmende mittel ATE323701T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27484001P 2001-03-09 2001-03-09

Publications (1)

Publication Number Publication Date
ATE323701T1 true ATE323701T1 (de) 2006-05-15

Family

ID=23049813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02710260T ATE323701T1 (de) 2001-03-09 2002-02-08 Triazolopyridine als entzündungshemmende mittel

Country Status (37)

Country Link
US (1) US6696464B2 (de)
EP (1) EP1370559B1 (de)
JP (1) JP4130774B2 (de)
KR (1) KR20030080087A (de)
CN (1) CN1496366A (de)
AP (1) AP2002002463A0 (de)
AR (1) AR036152A1 (de)
AT (1) ATE323701T1 (de)
BG (1) BG108133A (de)
BR (1) BR0207990A (de)
CA (1) CA2440222C (de)
CR (1) CR7013A (de)
CZ (1) CZ20032185A3 (de)
DE (1) DE60210755T2 (de)
DO (1) DOP2002000353A (de)
EA (1) EA200300864A1 (de)
EC (1) ECSP034762A (de)
EE (1) EE200300437A (de)
ES (1) ES2260415T3 (de)
GT (1) GT200200042A (de)
HR (1) HRP20030719A2 (de)
HU (1) HUP0303415A2 (de)
IL (1) IL156567A0 (de)
IS (1) IS6858A (de)
MA (1) MA26991A1 (de)
MX (1) MXPA03008144A (de)
NO (1) NO20033969L (de)
NZ (1) NZ526528A (de)
OA (1) OA12552A (de)
PA (1) PA8541001A1 (de)
PE (1) PE20030010A1 (de)
PL (1) PL363959A1 (de)
SK (1) SK10272003A3 (de)
TN (1) TNSN02022A1 (de)
UY (1) UY27199A1 (de)
WO (1) WO2002072579A1 (de)
ZA (1) ZA200304983B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (de) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Kondensierte heterozyklische Succinimid-Verbindungen und Analoga daraus, Modulatoren der nuklearen Hormonrezeptorfunktion
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
US7087636B2 (en) * 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
DK1474395T3 (da) * 2002-02-12 2008-02-11 Smithkline Beecham Corp Nicotinamidderivater, der er nyttige som p38-inhibitorer
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
CA2496812A1 (en) * 2002-08-30 2004-03-11 Pfizer Products Inc. Novel processes and intermediates for preparing triazolo-pyridines
BRPI0407384A (pt) * 2003-02-14 2006-02-21 Pfizer Prod Inc piridinas-triazóis como compostos antiinflamatórios
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004078116A2 (en) 2003-03-03 2004-09-16 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EP1708709A1 (de) * 2003-12-18 2006-10-11 Pfizer Products Incorporated Verfahren zur behandlung von akuter entzündung bei tieren mit p38 map-kinasehemmern
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
EP1765825A1 (de) * 2004-06-25 2007-03-28 Amgen Inc. Zur behandlung von durch cytokine vermittelten krankheiten und anderen krankheiten geeignete kondensierte triazole und indazole
KR100871535B1 (ko) 2004-08-12 2008-12-05 화이자 인코포레이티드 Ｐ38 ｍａｐ 키나아제 억제제로서의트리아졸로피리딘일설판일 유도체
AU2005273612B2 (en) 2004-08-12 2010-10-14 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
CA2577478A1 (en) * 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
EP1781655A2 (de) * 2004-08-18 2007-05-09 Pharmacia & Upjohn Company LLC Triazolopyridinverbindungen zur entzündungsbehandlung
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
PE20070182A1 (es) 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
EP1981851B1 (de) 2006-01-31 2012-01-25 Array Biopharma, Inc. Kinasehemmer und ihre anwendungsverfahren
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
CN101553224A (zh) 2006-10-06 2009-10-07 艾博特公司 新型咪唑并噻唑和咪唑并唑
LT3034075T (lt) 2006-11-22 2018-11-26 Incyte Holdings Corporation Imidazotriazinai ir imidazopirimidinai kaip kinazės inhibitoriai
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
EP2170337A4 (de) * 2007-06-28 2013-12-18 Abbvie Inc Neue triazolopyridazine
MX2010002312A (es) 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2108641A1 (de) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Neue substituierte Spiro[Cycloalkyl-1,3'-indo]-2'(1'H)-on-Derivate und ihre Verwendung als p38 mitogen-activated Kinase Inhibitoren
EP2113503A1 (de) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. Neue substituierte Indolin-2-on- Derivate und ihre Verwendung als p39 mitogen-activated Kinase Inhibitoren
NZ589622A (en) 2008-05-21 2012-10-26 Incyte Corp Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US8987251B2 (en) 2008-08-19 2015-03-24 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US8895550B2 (en) 2008-08-19 2014-11-25 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之***吡啶化合物
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
PL2464645T3 (pl) 2009-07-27 2017-12-29 Gilead Sciences, Inc. Skondensowane heterocykliczne związki jako modulatory kanałów jonowych
EP2322176A1 (de) 2009-11-11 2011-05-18 Almirall, S.A. Neue 7-Phenyl-[1,2,4]triazol[4,3-a]pyridin-3(2H)on-Derivate
AU2011269788B2 (en) 2010-02-03 2015-12-10 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
CN103370316B (zh) * 2010-11-16 2015-06-24 南京英派药业有限公司 作为细胞增殖抑制剂的3-芳基-6-芳基-[1,2,4]***并[4,3-a]吡啶及其应用
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
PL2678329T3 (pl) 2011-02-25 2016-06-30 Array Biopharma Inc Związki triazolopirydyny jako inhibitory kinaz pim
MX361350B (es) 2011-05-10 2018-12-04 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal de sodio.
NO3175985T3 (de) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
EP2968280A4 (de) * 2013-03-14 2016-08-10 Genentech Inc Substituierte triazolopyridine und verfahren zur verwendung davon
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
LT3691620T (lt) 2017-10-05 2022-09-26 Fulcrum Therapeutics, Inc. P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui
CN116514801A (zh) * 2022-01-20 2023-08-01 四川大学 2-苯基-[1,2,4]***并[1,5-a]吡啶类化合物、其氮氧化物及用途
CN114504636B (zh) * 2022-01-27 2023-09-26 华南理工大学 一种杏仁油烫伤膏及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576499A (en) * 1897-02-02 Gas apparatus
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
ES2140561T3 (es) 1993-09-17 2000-03-01 Smithkline Beecham Corp Proteina de union de farmacos.
IT1269176B (it) * 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5756499A (en) 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
WO1999061440A1 (en) 1998-05-26 1999-12-02 Smithkline Beecham Corporation Novel substituted imidazole compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
JP4634613B2 (ja) 1998-12-16 2011-02-16 アベンティス・フアーマ・リミテッド ヘテロアリール環状アセタール類
WO2000040243A1 (en) 1999-01-08 2000-07-13 Smithkline Beecham Corporation Novel compounds
EP2298311B1 (de) 1999-01-13 2012-05-09 Bayer HealthCare LLC Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

Also Published As

Publication number Publication date
WO2002072579A1 (en) 2002-09-19
US6696464B2 (en) 2004-02-24
EP1370559B1 (de) 2006-04-19
DOP2002000353A (es) 2002-10-15
UY27199A1 (es) 2002-10-31
BG108133A (bg) 2004-09-30
NZ526528A (en) 2005-02-25
EP1370559A1 (de) 2003-12-17
OA12552A (en) 2006-06-06
CZ20032185A3 (en) 2004-06-16
PE20030010A1 (es) 2003-01-29
CN1496366A (zh) 2004-05-12
CR7013A (es) 2003-11-25
DE60210755T2 (de) 2006-11-16
AP2002002463A0 (en) 2002-06-30
CA2440222A1 (en) 2002-09-19
HRP20030719A2 (en) 2005-04-30
MXPA03008144A (es) 2003-12-12
KR20030080087A (ko) 2003-10-10
IL156567A0 (en) 2004-01-04
BR0207990A (pt) 2004-04-27
US20030096838A1 (en) 2003-05-22
TNSN02022A1 (fr) 2005-12-23
ZA200304983B (en) 2004-06-29
IS6858A (is) 2003-06-23
EA200300864A1 (ru) 2003-12-25
CA2440222C (en) 2008-11-18
AR036152A1 (es) 2004-08-18
HUP0303415A2 (hu) 2004-01-28
PL363959A1 (en) 2004-11-29
ES2260415T3 (es) 2006-11-01
ECSP034762A (es) 2003-10-28
GT200200042A (es) 2003-02-11
NO20033969L (no) 2003-10-13
NO20033969D0 (no) 2003-09-08
PA8541001A1 (es) 2003-05-14
MA26991A1 (fr) 2004-12-20
JP2004522799A (ja) 2004-07-29
JP4130774B2 (ja) 2008-08-06
EE200300437A (et) 2004-02-16
DE60210755D1 (de) 2006-05-24
SK10272003A3 (sk) 2004-07-07

Similar Documents

Publication Publication Date Title
ATE323701T1 (de) Triazolopyridine als entzündungshemmende mittel
DE60234264D1 (de) Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen
ATE516030T1 (de) Benzimidazolidinon-derivate als muscarinische mittel
DE602004012891D1 (de) Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
MA27043A1 (fr) Azaindoles
DE50303960D1 (de) Carbamat-substituierte pyrazolopyridine
ATE391531T1 (de) Schweisshemmende mittel
NO20034176L (no) Pyrazolopyrimidiner som terapeutiske midler
NO20034177L (no) Pyrazolopyrimidiner som terapeutiske midler
ATE368041T1 (de) Neue pyrrolderivate als pharmazeutische mittel
DE60208385D1 (de) Antineoplasische kombinationspräparate
DE69935807D1 (de) Substituierte bizyclische derivate verwendbar als antitumor mittel
DE10297245T5 (de) Gleichspannungs-Wandlervorrichtung
ATE445610T1 (de) Neue, sich als antiproliferative mittel eignende benzimidazolderivate
DE60132618D1 (de) 4,6-diphenylpyridinderivate als entzündungshemmende mittel
DE50202178D1 (de) Neue sulfonat-substituierte pyrazolopyridinderivate
DE60214413D1 (de) Thiophen- und thiazolsulfonamide als antineoplastische mittel
DE60211100D1 (de) Spindelvorrichtung
DE60119982D1 (de) Heterozyklylalkylindole oder -azaindole als 5-hydroxytryptamine-6 liganden
DE60028085D1 (de) Piperidinyloxy- und pyrrolidinyloxyphenyloxazolidinone als antibakterielle mittel
DE60004207D1 (de) Bizyklische oxazolidinone als antibakterielle mittel
DE69917451D1 (de) Sulfonylbenzolverbindungen als analgetische und entzündungshemmende mittel
DE10196071T1 (de) Elektrisches Spindelantriebssystem
DE60207318D1 (de) Festes kosmetisches Mittel
DE60214138D1 (de) Isoxazolin-derivate als antidepressiva

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties